These approvals cover patients who have undergone a nephrectomy, or the removal of metastatic lesions, and are now facing an intermediate-high or high risk of the disease returning. The decision follows results from the LITESPARK-022 trial, a Phase 3 study involving 1,841 participants. Data indicated that the Keytruda and Welireg regimen reduced the risk of cancer recurrence, metastasis, or death by 28% when measured against Keytruda paired with a placebo.

While these results demonstrate improved disease-free survival, researchers have not yet tracked patients long enough to determine if the regimen provides a definitive increase in overall survival. Merck noted that this milestone represents the first time a PD-1 inhibitor has been combined with an HIF-2 inhibitor for clinical use. As an adjuvant therapy, the treatment aims to prevent the cancer from rebounding in the critical period immediately following surgical intervention.